Vanucizumab Human Monoclonal Antibody
Vanucizumabis a research-grade recombinant antibody targeting Vascular endothelial growth factor A. Produced in mammalian cells with native-like glycosylation. Highlights Research Grade: For PK/PD studies, assay development, and ADA research. Native Glycosylation: Mammalian expression ensures native-like patterns.
Product Specifications
Product Name Alternative
Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A, ANG-2, ANGPT2, Angiopoietin-2
UniProt
P15692, O15123
Reactivity
Human
Clonality
Monoclonal
Conjugation
Unconjugated
Purification
Protein A/G purified from cell culture supernatant.
Concentration
Lot dependent
Purity
>95% purity as determined by SDS-PAGE.
Form
Liquid
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Tested Applications
ELISA, FA, FACS, In vivo
Host or Source
Human Humanized
Preservative
0.01M PBS, pH 7.4.
Isotype
Human IgG1 - kappa - lambda with half-IG VL-CH1/VH-CK crossover
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
KIAA0319 (Dyslexia-associated Protein KIAA0319, DLX2, DYLX2, MGC176717) (HRP)
KIAA0319 (Dyslexia-associated Protein KIAA0319, DLX2, DYLX2, MGC176717) (HRP)
CYP1A2 (Cytochrome P450 1A2, CYPIA2, Cytochrome P (3) 450, Cytochrome P450 4, Cytochrome P450-P3) (MaxLight 490)